What question did this study set out to answer?

This study aims to investigate dermorphin's effect on the pituitary-adrenocortical system and hormone release.

April 27, 2026Open Access

Dermorphin reduces the metyrapone-evoked release of adrenocorticotropin, beta-endorphin, and beta-lipotropin in man.

View Full Paper

Ask AI

Bookmark

Authors

Randomized trial evaluates dermorphin's effect on adrenocorticotropic hormones in men, indicating peptide involvement in adrenal regulation.

This study aims to investigate dermorphin's effect on the pituitary-adrenocortical system and hormone release.
Six normal men received oral metyrapone to stimulate ACTH, beta-lipotropin, and beta-endorphin secretion.
Dermorphin was infused at a dose of 5.5 micrograms/kg/min for 30 minutes.
Comparison was made between hormone release during dermorphin and saline infusions.
Dermorphin infusion significantly suppressed metyrapone-evoked ACTH release.
Beta-lipotropin and beta-endorphin levels also declined significantly during dermorphin infusion.
Indicates potential for opioid peptides in regulating pituitary-adrenocortical activity.

Degli et al. (1985) studied this question.

View Full Paper

Ask AI

Bookmark

Randomized trial evaluates dermorphin's effect on adrenocorticotropic hormones in men, indicating peptide involvement in adrenal regulation.